ClinicalTrials.gg
CompletedNCT03011996Updated May 12, 2017

To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration

A Phase 1 interventional study of CLR 500mg and CJ-12420 100mg in Drug Interaction, Pharmacokinetic and Pharmacodynamic, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled May 2016, registered Dec 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
All
01

Study summary

Cohort 1

To evaluate the pharmacokinetic interactions of CJ-12420 after multiple oral doses of CJ-12420 given alone or in combination with amoxicillin/clarithromycin in healthy subjects.

Cohort 2

To evaluate the pharmacodynamic profiles of CJ-12420 after multiple oral doses of CJ-12420 in combination with amoxicillin/clarithromycin in healthy subjects as compared to an active control group, i.e., pantoprazole in combination with amoxicillin/clarithromycin.

Read the detailed description

To evaluate the pharmacokinetic the drug-drug interaction of CJ-12420 and amoxicillin/clarithromycin and investigate the pharmacodynamic of co-administration of CJ-12420 and amoxicillin and clarithromycin.

02

Conditions studied

  • Drug Interaction
  • Pharmacokinetic
  • Pharmacodynamic
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male volunteers aged ≥19 and ≤45 years at screening;
  2. No congenital or chronic disease, and no morbid symptoms or findings on screening tests;
  3. (BMI) ≥18.5 and ≤28 kg/m2;
  4. Considered eligible based on medical examinations (including interview, vital signs, 12-lead , physical exam and laboratory tests) which are set and performed in accordance with the nature of product by the investigator;
  5. Voluntary consent to participate in the study after being fully informed of purpose and procedures of the study, and profiles of investigational product prior to the participation;
  6. For Cohort 2, positive on 13C urea breath test.

Exclusion criteria

Exclusion Criteria:

  1. Medical history

    1. History or current evidence for diseases considered by the investigator including hepatic, renal, gastrointestinal, respiratory, musculoskeletal, endocrine, neurologic, hemato-oncological, urinary, or cardiovascular (including cardiac arrhythmia) diseases;
    2. History of gastrointestinal diseases (such as gastritis, gastrodynia, gastroesophageal reflux disease, Crohn's disease and ulcer) or abdominal surgery (except for simple appendectomy or herniotomy) which are considered to have potential effect on drug absorption by the investigator;
    3. For Cohort 2, previous treatment failure for H. pylori eradication.
  2. Laboratory tests and

    1. or ALT ≥ 1.25 x (ULN);
    2. Total ≥ 1.5 x ULN;
    3. calculated by CKD-EPI formula \< 80 mL/min;
    4. Any clinically relevant ECG abnormalities.
  3. Allergy and drug abuse

    1. History of to drugs containing products (penicillins, cephems, macrolides, pantoprazole and benzimidazole) and other drugs (including aspirin and antibiotics);
    2. History of drug abuse or positive on drug screening test.
  4. Drug/dietary restrictions

    1. Medications (including herbal supplements) or abnormal diet (e.g., grapefruit juice > 1 L/day, excessive garlic, broccoli, kale, etc.) which may have effect on absorption, distribution, metabolism and excretion of investigational products within 28 days prior to the first study dose;
    2. Use of prescription drugs, over-the-counter drugs (OTCs) or vitamins within 10 days prior to the first study dose;
    3. Participating in other study and receive investigational product within 3 months prior to the first study dose.
  5. Blood donation and transfusion

    1. Whole blood donation within 60 days prior to the first study dose;
    2. Donation of blood components or transfusion within 30 days prior to the first study dose.
  6. Pregnancy and

    1. Pregnant or breast-feeding;
    2. Subject or his partner's inability to use of medically qualifying dual-contraceptive methods or medically acceptable contraception (including intrauterine device with established pregnancy failure rate, barrier methods with spermicide, vasectomy, tubectomy, tubal ligation and hysterectomy) from screening to 30 days of the last dose of investigational product.
  7. Others

    1. Heavy use of alcohol (average alcohol intake ≥30 g/day) or positive on alcohol test;
    2. Heavy smoker (>10 cigarettes/day);
    3. Caffeine intake > 400 mg/day;
    4. Any clinically relevant findings considered inappropriate for study participation at the discretion of the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    CJ-12420 100mg

    CJ-12420 100mg BID for 5 days

    Drug: CJ-12420 100mg

  • Experimental
    CJ-12420 50mg + CLR 500mg + AMX 1g

    coadministration of CJ-12420 50mg and CLR 500mg/AMX 1g BID for 7 days

    Drug: CLR 500mg · Drug: CJ-12420 50mg · Drug: AMX 1g

  • Active comparator
    Pantoprazole 40mg + CLR 500mg + AMX 1g

    coadministration of Pantoprazole 40mg and CLR 500mg/AMX 1g BID for 7 days

    Drug: CLR 500mg · Drug: AMX 1g · Drug: Pantoprazole 40mg

  • Experimental
    CJ-12420 100mg + CLR 500mg + AMX 1g

    coadministration of CJ-12420 100mg, CLR 500mg/AMX 1g BID for 7 days

    Drug: CLR 500mg · Drug: CJ-12420 100mg · Drug: AMX 1g

  • Experimental
    CLR 500mg/AMX 1g

    CLR 500mg/AMX 1g BID for 5 days

    Drug: CLR 500mg · Drug: AMX 1g

  • Experimental
    CJ-12420 100mg + CLR 500mg/AMX 1g

    coadministration of CJ-12420 100mg and CLR 500mg/AMX 1g BID for 7 days

    Drug: CLR 500mg · Drug: CJ-12420 100mg · Drug: AMX 1g

Interventions

  • Cohort 1: bid for 5 days Cohort 2: bid for 7 days

    Also known as: Clarithromycin 500mg

  • Cohort 1: bid for 5 days Cohort 2: bid for 7 days

  • Cohort 2: bid for 7 days

  • DrugAMX 1g

    Cohort 1: bid for 5 days Cohort 2: bid for 7 days

    Also known as: Amoxicillin 1g

  • DrugPantoprazole 40mg

    Cohort 2: bid for 7 days

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax) of CJ-12420, clarithromycin and amoxicillin

    Time frame: Up to 120 hours

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC) of CJ-12420, clarithromycin and amoxicillin

    Time frame: Up to 120 hours

  2. Time of maximum observed concentraion(tmax) of CJ-12420, clarithromycin and amoxicillin

    Time frame: Up to 120 hours

  3. Half life(t1/2) of CJ-12420, clarithromycin and amoxicillin

    Time frame: Up to 120 hours

  4. Oral clearance at steady state(CLss/F) of CJ-12420, clarithromycin and amoxicillin

    Time frame: Up to 120 hours

  5. Apparent volume of distribution at steady state(Vdss/F) of CJ-12420, clarithromycin and amoxicillin

    Time frame: Up to 120 hours

  6. median pH

    Data from the pH probe monitoring

    Time frame: Up to 24 hours

  7. Time at pH > 3 (%)

    the percent of time the pH as data from the pH probe monitoring

    Time frame: Day -1, Day 1, Day 7 up to 24 hours

  8. Time at pH > 4 (%)

    the percent of time the pH as data from the pH probe monitoring

    Time frame: Day -1, Day 1, Day 7 up to 24 hours

  9. Time at pH > 6 (%)

    the percent of time the pH as data from the pH probe monitoring

    Time frame: Day -1, Day 1, Day 7 up to 24 hours

07

Study locations

1 site
  • Inje University Busan Baik Hospital
    Busan, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Feb 2017, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2016
First posted
Jan 6, 2017
StartActual
May 2016
Primary completionActual
Feb 2017
CompletionActual
Feb 2017
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03011996
Responsible party
Sponsor
First posted
Jan 6, 2017
Start date
May 2016
Primary completion
Feb 2017
Completion
Feb 2017
Last update
May 12, 2017

Study contacts

Jae-Gook Shin
principal investigator · Inje university college of medicine Busan Paik Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clarithromycin · Tegoprazan

Start the discussion